Physician profile
Steven Vogl
NPI 1477516755
$3,128.03
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $349 · 2021: $697 · 2022: $1,022 · 2023: $333 · 2024: $41.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,211.35 | 2019-2023 | Tagrisso, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $745.70 | 2019-2023 | |
| Janssen Biotech, INC. | $219.70 | 2019-2022 | |
| Pfizer INC. | $177.82 | 2019-2023 | |
| Daiichi Sankyo INC. | $141.15 | 2021-2023 | Enhertu |
| Merck Sharp & Dohme LLC | $136.04 | 2019-2022 | |
| Foundation Medicine, INC. | $103.63 | 2022-2023 | |
| Lilly USA, LLC | $73.07 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $56.60 | 2019-2022 | |
| Eisai INC. | $49.78 | 2019 | |
| Incyte Corporation | $38.06 | 2019-2020 | |
| Ge Healthcare | $34.95 | 2021 | |
| Rigel Pharmaceuticals, INC. | $25.31 | 2019 | |
| Seagen INC. | $25.06 | 2022 | |
| Astellas Pharma US INC | $24.65 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $22.42 | 2023 | Tazverik |
| Jazz Pharmaceuticals INC. | $21.42 | 2022 | |
| Taiho Oncology, INC. | $21.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Vogl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.